SRRK Scholar Rock, Inc.
Scholar Rock, Inc. (SRRK) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.87 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.6% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Scholar Rock, Inc.
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Sector
Healthcare
Industry
Biotechnology